Why Investors Pay Attention to Founder Compensation
Why founder salaries, loans, and deferred pay are signals investors read closely when assessing alignment in an early-stage deal.
ChaosBio Investor Network
Receive curated life science investment opportunities
Join the Investor Network.
Why Join
What being on the list gets you.
- Curated therapeutics, medical device, digital health, and life sciences infrastructure opportunities
- Concise investment memos that state the risks as plainly as the opportunity
- No obligation to invest, ever
- Free to join, with no fees to be on the list
- Opportunities only when there is a deal worth sharing — no filler, no newsletter cadence to keep up with
Investment Focus
Early-stage life science.
Therapeutics
Small molecules, biologics, and ATMPs targeting diseases with high unmet medical need.
Medical Devices
Devices that improve patient outcomes or create a new standard of care.
Digital Health & Diagnostics
AI, digital, and diagnostic approaches addressing a clear clinical or workflow problem.
Life Sciences Infrastructure
Research tools, laboratory automation, biomanufacturing, and the platforms and software that enable modern drug development.
How It Works
Three steps, no obligation.
- 01
You join the network
A short form: name, email, and a few optional questions about your investing profile. Around a minute, and there is no fee or commitment.
- 02
You receive curated memos
Only when a company has been reviewed and there is a genuine fit with your stated interests — never a general newsletter, never a volume play.
- 03
You decide, with no obligation
Every memo states the risks as plainly as the opportunity. Expressing interest is non-binding until definitive documents are signed, and you can unsubscribe from deal emails at any time.
Why ChaosBio
Investors fund risk reduction.
Great science matters, but it is rarely the whole story. Every opportunity shared here has been read against the same questions: is the problem meaningful, is the evidence credible, is the development path realistic, is the team complete, and are the key risks being reduced in a way that later investors and acquirers will trust.
That read comes from a pharmaceutical R&D operator's perspective, not a generalist one, and every memo states the risks as plainly as the opportunity. A memo that only sells is not worth reading.
Questions
Investor FAQ
What does it cost to join?
Nothing. Joining the Investor Network is free and carries no commitment of any kind.
How often will I hear from you?
Only when there is a curated opportunity worth sharing. There is no newsletter and no cadence to keep up with.
Am I obligated to invest?
No. Everything shared is an opportunity to consider, and expressing interest is explicitly non-binding until definitive documents are signed.
Do I need to be an accredited investor?
The form asks, because it affects what can be shared with you, but you are welcome to join either way.
What will I actually receive?
A concise investment memo covering the company, the round, why ChaosBio is sharing it, and the key risks as we see them.
Can I leave?
Yes. Every email carries an unsubscribe link that stops deal emails without removing you from the wider ChaosBio network.
Journal
How ChaosBio evaluates opportunities.
An Idea Needs Evidence
Why a compelling scientific idea becomes investable only when evidence begins to reduce its most important risks.
What Makes Me Pause in an AI Healthcare Pitch
Five questions I ask to separate genuine healthcare innovation from AI hype.